Heart Failure in African-Americans

Login or register to view PDF.
Citation
US Cardiology 2006;2005:2(1):1-6

Pages

The US population is characterized by significant racial/ethnic demographic transitions with an emerging number of special populations at risk for cardiovascular disease. Amongst the special populations with heart disease, it is heart failure in African-Americans that has become the prototypical model.

Heart FailureÔÇöAn Enigmatic Disease in African-Americans

Chronic heart failure is no longer a fatal diagnosis. Rather, it is a treatable disease entity with significant improvements in morbidity and mortality expected from the best application of evidence-based treatment strategies. However, a critical review of clinical trials in heart failure questions whether or not African-Americans with heart failure are able to realize these significant improvements in outcomes. This concern is, in part, driven by the inconsistent representation of African-Americans in cardiovascular clinical trials, and is further complicated by the limitations of retrospective subgroup analyses of underrepresented subgroups. Despite these important provisos, lessons have been learned from the clinical trials that define heart failure in African-Americans.

African-Americans have a higher prevalence of heart failure compared with white Americans (3% versus 2%). When heart failure occurs in African-Americans, it has an enigmatic natural history. The disease occurs at an earlier age, and both the degree of left ventricular (LV) dysfunction and apparent disease severity are worse at the time of diagnosis. Hospitalization rates are higher in African-Americans, and concerns regarding decreased survival rates have not been resolved. The imputed etiology of LV dysfunction in African-Americans is more likely to be non-ischemic than in white Americans. As seen in Figure 1, there is a lower likelihood of documented ischemic heart disease as the putative cause of LV dysfunction and a greater likelihood of non-ischemic, principally hypertensive, disease as the sole potential explanation for LV dysfunction.

A number of plausible explanations for excess heart failure in African-Americans have been proposed, with no single proven causative theory. The psychosocial burdens of the African-American culture are easily recognizable and undoubtedly important, and no discussion about cardiovascular health and outcomes in African-Americans can be complete without acknowledging that healthcare disparities do exist. The deleterious influence of malignant hypertension and the burden of obesity and diabetic disease cannot be overlooked. Genomic medicine has much potential to uncover these important subgroup issues but is also quite incipient and remains problematic in interpretation.

Pages

References
  1. US Census Bureau.Available at: http://www.census.gov/ipc/www/usinterimproj/natprojtab01b.pdf (accessed October 2005).
  2. American Heart Association, African-Americans and Cardiovascular Diseases: Statistics, available at http://www.americanheart.org/downloadable/heart/1103831662755FS01AF05.pdf (accessed January 2005).
  3. Yancy C W,Heart failure in African-Americans: a cardiovascular enigma, J. Card. Fail. (2000);6: pp. 183-186.
    Crossref | PubMed
  4. Dries D L, Exner D V, Gersh B J, Cooper H A, Carson P E, Domanski M J,Racial differences in the outcome of left ventricular dysfunction, N. Engl. J. Med. (1999);340: pp. 609-616.
    Crossref | PubMed
  5. The Beta-Blocker Evaluation of Survival Trial Investigators,A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure, N. Engl. J. Med. (2001);344: pp. 1,659-1,667.
    Crossref | PubMed
  6. Packer M, Coats A J S, Fowler M B et al., (for the Carvedilol Prospective Randomized Cumulative Survival Study Group), Effect of carvedilol on survival in severe chronic heart failure, N. Engl. J. Med. (2001);344: pp. 1,651-1,658.
    Crossref | PubMed
  7. Cohn J N, Archibald D G, Ziesche S et al., Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study,N. Engl. J. Med. (1986);314: pp. 1,547-1,552.
    Crossref | PubMed
  8. Cohn J N, Johnson G, Ziesche S et al., A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure,N. Engl. J. Med. (1991);325: pp. 303-310.
    Crossref | PubMed
  9. Smedley B D, Stith A Y, Nelson A R (eds), Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care,The National Academies Press,Washington D C (2003).
  10. Exner D V, Dries DL, Domanski M J, Cohn J N, Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction, N. Engl. J. Med. (2001);344: pp. 1,351-1,357.
    Crossref | PubMed
  11. Shekelle P G, Rich M W, Morton S C et al., Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials, J.Am. Coll. Cardiol. (2003);41: pp. 1,529-1,538.
    Crossref | PubMed
  12. Yancy C W, Fowler M B, Colucci W S et al., (for the US Carvedilol Heart Failure Study Group), Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure, N. Engl. J. Med. (2001);344: pp. 1,358-1,365.
    Crossref
  13. Carson P, Ziesche S, Johnson G, Cohn J N (for the Vasodilator-Heart Failure Trial Study Group),Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials, J. Card. Fail. (1999);5: pp. 178-187.
    Crossref | PubMed
  14. Kalinowski L, Dobrucki I T, Malinski T, Race-specific differences in endothelial function: predisposition of African-Americans to vascular diseases, Circulation (2004);109: pp. 2,511-2,517.
    Crossref | PubMed
  15. Taylor A L, Ziesche S,Yancy C et al., (for the African-American Heart Failure Trial Investigators), Combination of isosorbide dinitrate and hydralazine in blacks with heart failure, N. Engl. J. Med. (2004);351: pp. 2,049-2,057.
    Crossref | PubMed
  16. Hare J M,Nitroso-redox balance in the cardiovascular system, N. Engl. J. Med. (2004);351(20): pp. 2,112-2,114.
    Crossref | PubMed